Biocom California’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom California has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.
Vice President, Business Development at Amgen
Jessica Droge is Vice President of Business Development at Amgen, where she leads the Search and Evaluation as well as the Business Intelligence efforts for drug therapeutics and technologies. Her group identifies and assesses over 2500 external opportunities per year in support of all licensing, collaboration, and acquisition deals.
Jessica brings over 25 years of drug development experience to her role, with expertise in both small and large molecules as well as medical devices. Prior to being in Business Development, she led clinical development activities to support global scientific, regulatory, and commercial strategies across multiple therapeutic areas in the settings of academic, start-up, and large companies.
She began her career in drug development by leading large clinical trials in experimental vaccines for the Centers for Disease Control and UCLA’s Center for Vaccine Research. This was followed by her work heading the Clinical Affairs departments at a series of private companies. Jessica joined Amgen in 2005 as part of the Clinical Development group and transitioned to Business Development in 2011.
Jessica received her undergraduate degree from University of California San Diego (UCSD) and her PhD from UCLA.